Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Brain Behav. 2020 Aug;10(8):e01697. doi: 10.1002/brb3.1697. Epub 2020 Jun 16.
To identify possible prognostic factors in children with head and neck rhabdomyosarcoma (RMS).
A total of 98 patients with head and neck RMS were enrolled in this retrospective study from February 2005 to September 2017. Prognostic factors were evaluated by univariate and multivariate analysis using Cox's proportional hazards model. Survival curves were calculated by Kaplan-Meier method.
At the study closing date, there were 60 patients alive, 37 patients died, one patient was lost to follow-up, and 47 patients relapsed. The median disease-specific survival was 60.00 ± 25.36 months, and the overall survival (OS) rate was 61.9%. Complete remission was associated with a longer disease-specific survival (86.6%) compared with partial remission (6.7%). In addition, patients with age >3 years had better OS rate (69.0%) compared with age ≤3 years (42.3%). Univariate and multivariate analysis showed that chemotherapy efficacy and age were prognostic factors of disease-specific survival.
Improvement in outcome was obtained with comprehensive treatment for head and neck RMS. Both chemotherapy efficacy and age of patients were prognostic factors for children with head and neck RMS, which provide some valuable information for further treatment.
旨在确定头颈部横纹肌肉瘤(RMS)患儿的可能预后因素。
本回顾性研究纳入了 2005 年 2 月至 2017 年 9 月期间的 98 例头颈部 RMS 患儿。采用 Cox 比例风险模型进行单因素和多因素分析评估预后因素。采用 Kaplan-Meier 法计算生存曲线。
在研究截止日期,60 例患儿存活,37 例患儿死亡,1 例患儿失访,47 例患儿复发。疾病特异性中位生存时间为 60.00±25.36 个月,总生存率(OS)为 61.9%。完全缓解的疾病特异性生存时间(86.6%)明显长于部分缓解(6.7%)。此外,年龄>3 岁的患儿 OS 率(69.0%)明显高于年龄≤3 岁的患儿(42.3%)。单因素和多因素分析表明,化疗疗效和年龄是疾病特异性生存的预后因素。
对头颈部 RMS 进行综合治疗可改善预后。化疗疗效和患儿年龄均为头颈部 RMS 患儿的预后因素,为进一步治疗提供了有价值的信息。